Study Evaluating ReFacto in Hemophilia A

Wyeth is now a wholly owned subsidiary of Pfizer103 enrolled

Overview

To identify the causative mutations in previously untreated patients with hemophilia A enrolled in the ReFacto® clinical safety and efficacy study CTN 93-R833-0XX/C9741-28, using two established hemophilia mutation testing laboratories (one in Europe and one in North America).

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Enrollment

103

Conditions

Hemophilia A

Interventions

BDDrFVIIDRUG

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who were or are enrolled in Study CTN 93-R833-0XX/C9741-28, and have been treated with ReFacto® during this study are eligible for participation. * The patient (or legal guardian) must be willing to give written informed consent before any study-related procedures are performed. * A blood sample will be collected from each patient for the purpose of this study and will be analyzed at one or both of the designated central laboratories. Exclusion Criteria: * Any condition which, in the investigator's opinion, places the patient at undue risk.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.